Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tresiba Vs. Lantus: Novo Nordisk Scores A Win In Second Head-To-Head

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo revealed top-line results from SWITCH 1, showing Tresiba was superior to Lantus on a secondary endpoint of severe hypoglycemia in the maintenance period in type 1 diabetics, a positive after Tresiba failed to show superiority on the endpoint in another trial, SWITCH 2, in type 2 diabetes.


Related Content

Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts